EVE COUNT · PROJECT Q-ROTATE
Investor Deck
Quantinuum Singapore Grand Challenge 2026 · Chemistry Track

The Decentralized Quantum Testing Facility for Sovereign Biopharma

Screening proprietary drug candidates on trapped-ion quantum hardware—without their raw 3D molecular coordinates ever leaving the lab.

The Core Tech

Continuous Lie Group Rotation

Replaces 40 years of classical $O(N^3)$ Cartesian grid searching with unitary $SU(2)^{\otimes n}$ state manifold burrowing.

1,000x+ algorithmic speedup
The Commercial Moat

Zero-Exposure IP Screening

Ancilla-mediated SWAP test evaluates structural fit using quantum state overlap. Raw atomic coordinates never touch the cloud.

0 Coords transmitted (Eve Count = 0)
The Hardware Target

Quantinuum Trapped Ions

Zero SWAP gate overhead. 62 PhasedX and 32 ZZPhase gates per screen. Built for the upcoming Helios QPU in Singapore.

~13.6 HQCs per 100-shot circuit
The Industry Bottleneck

The $500M Pharma Dilemma: Why Cloud Quantum Is Stalled

Biopharma spends hundreds of millions synthesizing proprietary molecules. They desperately need quantum compute speed, but will never upload their unpatented IP to public clouds.

1. The Intellectual Property Wall

Corporate Espionage Risk

If an enterprise uploads raw 3D Cartesian coordinates $(x,y,z)$ of a new drug scaffold to an external server or cloud quantum computer, any rogue operator, vendor breach, or insider can steal the entire molecular patent blueprint before filing.

2. The Classical Computational Wall

The $O(N^3)$ "Mountain Hike"

Classical docking software (Schrödinger, AutoDock) discretizes 3D space into cubic voxels. They step through millions of rotational angles angle-by-angle, burning megawatts of cluster energy and continually slipping into local energy traps.

The Intuition · Zero Math Required

Why "Eve Count" & Why This Method Is Clever

In quantum information theory, "Eve" is the textbook eavesdropper. Here is how we guarantee an eavesdropper count of zero.

The Classical Way

A Locksmith with a Ruler

Traditional tools try to see if a drug fits a disease target by taking a ruler and measuring every tooth and groove of your secret master key, then wandering through a dark 3D maze testing millions of orientations.

❌ Exposes key geometry · Burns compute · Gets trapped in valleys
VS
Eve Count's Clever Way

Two Tuning Forks in Harmony

Imagine two tuning forks across a room. You don't measure the second fork. You strike your fork. If they share harmonic frequency, the second fork sings back through pure acoustic resonance.

✅ Zero coordinates stolen (Eve Count = 0) · Pure quantum phase overlap
Hardware-Validated Empirical Data

100% Convergence on 6 Real PDB Targets

Validated against real crystallographic structures from the RCSB Protein Data Bank and PubChem on native Quantinuum H2 gates.

Target Disease Pocket PDB ID Ligand Initial Misalignment RUS Loops Final Overlap P(0) Est. HQCs Speedup
11-cis Retinal / Rhodopsin RCSB 1U19 RET +45.0° 2 Loops 0.980 27.28 1,920×
GFP Chromophore RCSB 1EMA CRO +35.0° 4 Loops 0.990 54.56 1,056×
SARS-CoV-2 Mpro + Paxlovid RCSB 7VH8 4WI −50.0° 2 Loops 1.000 27.28 3,360×
COX-2 + Celecoxib RCSB 3LN1 CEL +80.0° 2 Loops 0.960 27.28 2,496×
Azobenzene Switch PubChem 2272 AZO −115.0° 5 Loops 0.940 68.20 538×
H2 Hardware Benchmark Exact QM H2 +15.0° 1 Loop 0.990 13.64 384×
Commercial Architecture & GTM

The "Quantum CRO" Business Model

We turn external partner labs into decentralized quantum testing facilities powered by Quantinuum trapped ions.

Stream 1 · High Volume

Pay-Per-Screen API

Billed per drug candidate screened ($250 – $500 per run). Hardware cost is only ~13.6 HQCs (~$25).

85%+ gross margin
Stream 2 · Predictable ARR

Enterprise Target Library

Annual subscriptions granting pharma partners dedicated quantum screening capacity and custom active-site manifolds.

$250k–$750k per partner/year
Stream 3 · Asymmetric Upside

Co-Dev Milestones

Milestone payments and royalties on successful lead molecules advancing from preclinical validation to Phase-I trials.

$5M–$25M per drug milestone
Ecosystem & Execution Roadmap

Positioned for the Arrival of Helios in Singapore

Anchored in Singapore’s National Quantum Strategy to drive domestic commercial drug discovery workloads.

Phase 1 · Current

Grand Challenge Finals

Published Aqora workspace v2.0.0; automated 14-test suite; 2 investor syndicates engaged for initial SAFE syndicate.

Phase 2 · Q4 2026

Helios Hardware Pilot

First physical hardware execution on Quantinuum trapped ions in Singapore; pilot screening LOIs with Biopolis & A*STAR labs.

Phase 3 · 2027

Commercial Quantum CRO

Fully automated API integration for regional biopharma hubs; sovereign drug discovery testing facility live.

Team Eve Count · Leadership & Advisory

Team Eve Count: Quantum, Systems & GTM

Deep technical quantum innovation backed by high-performance systems and institutional venture advisory.

Founder & Venture CTO

Gwendalynn Lim

B.Sc. (Hons) Applied Computing SIT, NTU SCTP AI/ML. Inventor of the continuous Lie group $\hat{U}_{\text{tube}}(\tau)$ formulation and Guppy dynamic loops.

Co-Founder & Architect

Benjamin Lim

Co-Founder @ Eve Count & Cybrdeck (1,500+ commits/yr). Lead architect for 3D Resonance Constellation WebGL telemetry and reactive systems.

Venture & GTM Advisor

James Sun

Founder @ Mamba Partners (11k+ network, ex. Goldman Sachs, Blackstone, Microsoft). Strategic advisor to Team Eve Count on venture syndication, biopharma licensing, and institutional GTM.

🎟️ RSVP for Oct 14 Technical Briefing (Luma) ↗ Explore the Live 3D Resonance Constellation ↗